Wouters OJ, McKee M, Luyten J. Estimated research and development investment needed to bring a new medicine to market, 2009–2018. JAMA. 2020;323:844–53.
Attwood MM, Rask-Andersen M, Schiöth HB. Orphan drugs and their impact on pharmaceutical development. Trends Pharmacol Sci. 2018;39:525–35.
Hughes DA, Poletti-Hughes J. Profitability and market value of orphan drug companies: a retrospective, propensity-matched case–control study. PLoS One. 2016;11:e0164681.
European Medicines Agency-EMA. 2021. https://www.ema.europa.eu/en/glossary/well-established-use. Accessed 18 June 2021.
Toumi M, Rémuzat C. Value added medicines: what value repurposed medicines might bring to society? J Mark Access Health Policy. 2017;5:1264717.
Lin S, Chan G, Palczewski K, Lewis K. Drug Repurposing: The New R&D. 2017. https://www.researchgate.net/publication/320877009_Drug_Repurposing_The_New_RD. Accessed 18 Mar 2021.
Petykó ZI, Inotai A, Holtorf AP, Brixner D, Kaló Z. Barriers and facilitators of exploiting the potential of value-added medicines. Expert Rev Pharmacoecon Outcomes Res. 2020;20:229–36.
Pushpakom S, Iorio F, Eyers PA, Escott KJ, Hopper S, Wells A, et al. Drug repurposing: progress, challenges and recommendations. Nat Rev Drug Discov. 2019;18:41–58.
Petykó ZI, Kaló Z, Espin J, Podrazilová K, Tesar T, Maniadakis N, et al. Development of a core evaluation framework of value-added medicines: report 1 on methodology and findings. Cost Eff Resour Alloc. 2021 (manuscript under review).
Phelps CE, Lakdawalla DN, Basu A, Drummond MF, Towse A, Danzon PM. Approaches to aggregation and decision making-a health economics approach: an ISPOR special task force report . Value Health. 2018;21:146–54.
Kolasa K, Zwolinski KM, Zah V, Kaló Z, Lewandowski T. Revealed preferences towards the appraisal of orphan drugs in Poland—multi criteria decision analysis. Orphanet J Rare Dis. 2018;13:67.
Iskrov G, Miteva-Katrandzhieva T, Stefanov R. Multi-criteria decision analysis for assessment and appraisal of orphan drugs. Front Public Health. 2016;4:214.
Schey C, Krabbe PFM, Postma MJ, Connolly MP. Multi-criteria decision analysis (MCDA): testing a proposed MCDA framework for orphan drugs. Orphanet J Rare Dis. 2017;12:10.
Gilabert-Perramon A, Torrent-Farnell J, Catalan A, Prat A, Fontanet M, Puig-Peiró R, et al. Drug evaluation and decision making in Catalonia: development and validation of a methodological framework based on multi-criteria decision analysis (MCDA) for orphan drugs. Int J Technol Assess Health Care. 2017;33:111.
Inotai A, Brixner D, Maniadakis N, Dwiprahasto I, Kristin E, Prabowo A, et al. Development of multi-criteria decision analysis (MCDA) framework for off-patent pharmaceuticals—an application on improving tender decision making in Indonesia. BMC Health Serv Res. 2018;18:1003.
Endrei D, Molics B, Agoston I. Multicriteria decision analysis in the reimbursement of new medical technologies: real-world experiences from Hungary. Value Health. 2014;17:487–9.
Suwantika AA, Purwadi FV, Zakiyah N, Puspitasari IM, Abdulah R, Diantini A, et al. Multi-criteria decision analysis to prioritize the introduction of new vaccines in Indonesia by using the framework of the strategic multi-attribute ranking tool for vaccines (SMART Vaccines). Expert Rev Vaccines. 2021.
Botwright S, Kahn AL, Hutubessy R, Lydon P, Biey J, Sidibe AK, et al. How can we evaluate the potential of innovative vaccine products and technologies in resource constrained settings? A total systems effectiveness (TSE) approach to decision-making. Vaccine. 2020;6:100078.
De Nardo P, Gentilotti E, Mazzaferri F, Cremonini E, Hansen P, Goossens H, et al. Multi-criteria decision analysis to prioritize hospital admission of patients affected by COVID-19 in low-resource settings with hospital-bed shortage. Int J Infect Dis. 2020;98:494–500.
Keeney RL, Raiffa H. Decisions with multiple objectives: preferences and value trade-offs. Cambridge: Cambridge University Press; 1993.
Belton V, Stewart TJ. Multiple criteria decision analysis: an integrated approach. Massachusetts: Kluwer Academic Publishers; 2002.
Inotai A, Nguyen HT, Hidayat B, Nurgozhin T, Kiet PHT, Campbell JD, et al. Guidance toward the implementation of multicriteria decision analysis framework in developing countries. Expert Rev Pharmacoecon Outcomes Res. 2018;18:585–92.
Wolf JA, Niederhauser V, Marshburn D, LaVela SL. Defining patient experience. Patient Exp. 2014;1:3.
Pontes C, Fontanet JM, Vives R, Sancho A, Gómez-Valent M, Ríos J, et al. Evidence supporting regulatory-decision making on orphan medicinal products authorisation in Europe: methodological uncertainties. Orphanet J Rare Dis. 2018;13:206.
Drummond M, Griffin A, Tarricone R. Economic evaluation for devices and drugs—same or different? Value Health. 2009;12:402–4.
Frieden TR. Evidence for health decision making—beyond randomized, controlled trials. N Engl J Med. 2017;377:465–75.
Murray E, Hekler EB, Andersson G, Collins LM, Doherty A, Hollis C, et al. Evaluating digital health interventions: key questions and approaches. Am J Prev Med. 2016;51:843–51.
Németh B, Kaló Z. European cooperation in health technology assessment implementation: the perspective of Central and Eastern European countries. Future Med. 2020;9:599–602.
Kristensen FB, Lampe K, Wild C, Cerbo M, Goettsch W, Becla L. The HTA Core Model®—10 years of developing an international framework to share multidimensional value assessment. Value Health. 2017;20:244–50.
EUnetHTA Joint Action 2, Work Package 8. HTA Core Model Version 3.0. 2016. http://www.corehta.info/model/HTACoreModel3.0.pdf. Accessed 18 Mar 2021.
Bodrogi J, Kaló Z. Principles of pharmacoeconomics and their impact on strategic imperatives of pharmaceutical research and development. Br J Pharmacol. 2010;159:1367–73.
Garrison LP Jr, Towse A, Briggs A, de Pouvourville G, Grueger J, Mohr PE, et al. Performance-based risk-sharing arrangements-good practices for design, implementation, and evaluation: report of the ISPOR good practices for performance-based risk-sharing arrangements task force. Value Health. 2013;16:703–19.
Kaló Z, Annemans L, Garrison LP. Differential pricing of new pharmaceuticals in lower income European countries. Expert Rev Pharmacoecon Outcomes Res. 2013;13:735–41.
Horizon Europe Programme (HORIZON)-Work Programme for Health 2021–2022. 2020. https://efmc.eu/wp-content/uploads/2021/02/Horizon-Europe-Programme-HORIZON-Work-Programme-2021-2022-for-Health-1.pdf. Accessed 18 June 2021.
Torjesen I. Covid-19: Hydroxychloroquine does not benefit hospitalised patients, UK trial finds. BMJ Online. 2020;369:m2263.
Mahase E. Hydroxychloroquine for covid-19: the end of the line? BMJ. 2020;369:m2378.
World Health Organization (WHO). Newsroom. 2020. https://www.who.int/news/item/04-07-2020-who-discontinues-hydroxychloroquine-and-lopinavir-ritonavir-treatment-arms-for-covid-19. Accessed 18 Mar 2021.
STAMP Working Group. Draft—proposal for a framework to support not-for-profit organisations in drug repurposing. 2019. https://ec.europa.eu/health/sites/health/files/files/committee/stamp/stamp_11_47_2_en.pdf. Accessed 18 Mar 2021.
Conti RM, Athey S, Frank RG, Gruber J. Generic drug repurposing for public health and national security: COVID-19 and beyond. Health Affairs Blog. 2020. https://www.healthaffairs.org/do/10.1377/hblog20201204.541050/full/. Accessed 18 June 2021.
Godman B, McCabe H, Leong D. Fixed dose drug combinations—are they pharmacoeconomically sound? Findings and implications especially for lower- and middle-income countries. Expert Rev Pharmacoecon Outcomes Res. 2020;20:1–26.